Equities

Fresh2 Group Ltd

Fresh2 Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4376
  • Today's Change-0.027 / -5.90%
  • Shares traded115.22k
  • 1 Year change-90.03%
  • Beta1.3627
Data delayed at least 15 minutes, as of Jun 07 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fresh2 Group Ltd, formerly AnPac Bio-Medical Science Co Ltd, is a biotechnology company mainly engaged in early cancer screening and detection. The Company is engaged in marketing and selling multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. The Company's CDA technology also assists physicians in cancer diagnosis, prognosis and recurrence. The Company provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, Internet, and Web3 transformation of start-ups and traditional enterprises.

  • Revenue in USD (TTM)1.62m
  • Net income in USD-13.42m
  • Incorporated2010
  • Employees75.00
  • Location
    Fresh2 Group Ltd801 Bixing Street, Bihu CountyLishui F4 323006ChinaCHN
  • Phone+86 57 820516666
  • Websitehttp://www.anpac.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Trinity Biotech plc (ADR)56.71m-33.88m18.93m380.00------0.3338-4.42-2.817.41-14.960.6251.693.67149,229.00-37.34-20.30-47.55-29.5434.2139.92-59.75-29.861.03-1.961.36---9.10-10.1515.41---31.08--
Synlogic Inc3.21m-73.22m18.97m6.00--1.41--5.92-10.62-10.620.45761.150.0495----534,166.70-113.09-40.57-134.57-43.82-----2,284.68-3,245.93----0.00008--185.685.9913.40---48.05--
Lumos Pharma Inc1.53m-37.13m19.07m33.00--1.09--12.51-4.59-4.590.18862.150.0332--8.0146,212.12-80.89-29.78-90.15-32.32-----2,434.69-2,937.61----0.00--34.67-30.31-9.57------
MEI Pharma Inc66.75m26.16m19.19m46.000.73370.3760.72380.28753.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Jaguar Health Inc10.14m-38.32m19.19m49.00--1.49--1.89-78.63-78.639.903.180.18060.23978.12206,938.80-69.22-95.29-122.86-163.5479.0767.28-383.35-522.281.39-2.780.6919---18.3617.1912.97------
KALA BIO Inc0.00-39.55m19.24m43.00--2.89-----15.15-15.150.002.370.00----0.00-63.15-57.83-76.71-69.32--57.06---1,553.61---12.260.8382---100.00--5.85---17.31--
AIM ImmunoTech Inc193.00k-31.12m19.28m26.00--4.57--99.91-0.637-0.6370.0040.0960.0072--0.21897,423.08-116.00-45.64-148.40-48.3574.09-231.75-16,123.32-11,695.01----0.3478--43.26-11.26-48.94--35.73--
Lyra Therapeutics Inc1.68m-68.88m19.51m109.00--0.2517--11.61-1.23-1.230.02971.270.0143----19,090.91-58.52-58.01-68.02-68.69-----4,099.82-6,235.31----0.00--14.314.60-13.39--95.14--
Viracta Therapeutics Inc0.00-47.99m19.65m40.00--3.49-----1.24-1.240.000.28210.00----0.00-75.51-86.35-112.64-106.38-------11,853.94---84.180.6277-------3.78------
Neurobo Pharmaceuticals Inc0.00-16.58m19.74m8.00--1.96-----3.26-3.260.002.050.00----0.00-68.36-95.57-108.01-135.64------------0.00------10.72--75.54--
Fresh2 Group Ltd - ADR1.62m-13.42m19.75m75.00--0.3961--12.17-4.03-4.460.36641.530.098320.861.4021,647.63-82.09-163.91-166.54--49.7359.81-834.90-625.630.4549-156.010.0001---33.0416.2014.16---9.49--
Polypid Ltd0.00-24.25m19.91m59.00--2.79-----12.35-12.350.001.490.00----0.00-84.94-76.92-120.03-89.61-----------28.720.5498------39.67---42.34--
Allied Corp21.51k-9.00m20.00m--------929.77-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Cumberland Pharmaceuticals, Inc.38.83m-8.42m20.44m91.00--0.7418--0.5263-0.596-0.5962.721.940.45420.88123.08426,654.70-9.83-7.03-14.07-9.5283.5479.95-21.65-17.641.21-37.100.3717---5.856.15-12.73---36.17--
Forte Biosciences Inc0.00-32.14m20.81m11.00--0.7245-----1.03-1.030.000.78820.00----0.00-93.54-72.06-104.30-82.27-------491,850.00----0.00-------126.79---46.29--
Sol Gel Technologies Ltd1.72m-22.86m21.03m36.00--0.6442--12.23-0.8222-0.82220.06191.170.0387--0.515447,777.78-51.40-31.60-57.29-35.49-----1,329.13-135.76----0.00---59.9864.50-82.52---33.78--
Data as of Jun 07 2024. Currency figures normalised to Fresh2 Group Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.03%Per cent of shares held by top holders
HolderShares% Held
RhumbLine Advisers LPas of 31 Mar 20246.68k0.03%
UBS Securities LLCas of 31 Mar 20240.000.00%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.